UroGen EBITDA from 2010 to 2025
| URGN Stock | USD 11.66 0.13 1.13% |
Check UroGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among UroGen Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . UroGen financial statements analysis is a perfect complement when working with UroGen Pharma Valuation or Volatility modules.
UroGen |
About UroGen Pharma Financial Statements
UroGen Pharma investors utilize fundamental indicators, such as EBITDA, to predict how UroGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Urogen Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 201 people.
Check out the analysis of UroGen Pharma Correlation against competitors. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.